Rogne: Penetrating peptides

Rogne developing topical peptide targeting IL-23 for mild to moderate psoriasis

Rogne Bioscience Inc. is developing a topical formulation of a naturally occurring human peptide that inhibits production of inflammatory cytokines to treat mild to moderate psoriasis without the side effects of topical steroids or injectable biologics.

The 90% of psoriasis patients with mild to moderate disease are typically treated with topical steroids or vitamin D. The latter is slow to take effect and has low efficacy. Topical steroids are effective but are used episodically due to side effects such

Read the full 780 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE